vs

Side-by-side financial comparison of Bristol Myers Squibb (BMY) and Chubb Limited (CB). Click either name above to swap in a different company.

Chubb Limited is the larger business by last-quarter revenue ($15.1B vs $11.5B, roughly 1.3× Bristol Myers Squibb). Bristol Myers Squibb runs the higher net margin — 23.3% vs 21.3%, a 2.0% gap on every dollar of revenue. On growth, Bristol Myers Squibb posted the faster year-over-year revenue change (11.0% vs 6.3%). Over the past eight quarters, Chubb Limited's revenue compounded faster (8.1% CAGR vs -3.0%).

Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid art...

Chubb Limited is an American–Swiss company incorporated in Zürich, and listed on the New York Stock Exchange (NYSE) where it is a component of the S&P 500. Chubb is a global provider of insurance products covering property and casualty, accident and health, reinsurance, and life insurance and is the largest publicly traded property and casualty insurance company in the world. Chubb operates in 55 countries and territories and in the Lloyd's insurance market in London. Clients of Chubb consist...

BMY vs CB — Head-to-Head

Bigger by revenue
CB
CB
1.3× larger
CB
$15.1B
$11.5B
BMY
Growing faster (revenue YoY)
BMY
BMY
+4.7% gap
BMY
11.0%
6.3%
CB
Higher net margin
BMY
BMY
2.0% more per $
BMY
23.3%
21.3%
CB
Faster 2-yr revenue CAGR
CB
CB
Annualised
CB
8.1%
-3.0%
BMY

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BMY
BMY
CB
CB
Revenue
$11.5B
$15.1B
Net Profit
$2.7B
$3.2B
Gross Margin
Operating Margin
25.0%
Net Margin
23.3%
21.3%
Revenue YoY
11.0%
6.3%
Net Profit YoY
8.8%
24.7%
EPS (diluted)
$8.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BMY
BMY
CB
CB
Q1 26
$11.5B
Q4 25
$12.5B
$15.1B
Q3 25
$12.2B
$16.1B
Q2 25
$12.3B
$14.8B
Q1 25
$11.2B
$13.4B
Q4 24
$12.3B
$14.2B
Q3 24
$11.9B
$14.8B
Q2 24
$12.2B
$13.8B
Net Profit
BMY
BMY
CB
CB
Q1 26
$2.7B
Q4 25
$1.1B
$3.2B
Q3 25
$2.2B
$2.8B
Q2 25
$1.3B
$3.0B
Q1 25
$2.5B
$1.3B
Q4 24
$72.0M
$2.6B
Q3 24
$1.2B
$2.3B
Q2 24
$1.7B
$2.2B
Gross Margin
BMY
BMY
CB
CB
Q1 26
Q4 25
67.2%
Q3 25
71.9%
Q2 25
72.5%
Q1 25
72.9%
Q4 24
61.0%
Q3 24
75.1%
Q2 24
73.2%
Operating Margin
BMY
BMY
CB
CB
Q1 26
Q4 25
11.8%
25.0%
Q3 25
25.5%
24.1%
Q2 25
14.5%
25.0%
Q1 25
26.5%
12.5%
Q4 24
1.4%
22.0%
Q3 24
14.1%
20.2%
Q2 24
10.5%
19.6%
Net Margin
BMY
BMY
CB
CB
Q1 26
23.3%
Q4 25
8.7%
21.3%
Q3 25
18.0%
17.3%
Q2 25
10.7%
20.0%
Q1 25
21.9%
10.0%
Q4 24
0.6%
18.2%
Q3 24
10.2%
15.7%
Q2 24
13.8%
16.1%
EPS (diluted)
BMY
BMY
CB
CB
Q1 26
Q4 25
$0.54
$8.05
Q3 25
$1.08
$6.99
Q2 25
$0.64
$7.35
Q1 25
$1.20
$3.29
Q4 24
$0.05
$6.31
Q3 24
$0.60
$5.70
Q2 24
$0.83
$5.46

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BMY
BMY
CB
CB
Cash + ST InvestmentsLiquidity on hand
$9.6B
Total DebtLower is stronger
$-42.2B
$15.7B
Stockholders' EquityBook value
$73.8B
Total Assets
$272.3B
Debt / EquityLower = less leverage
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BMY
BMY
CB
CB
Q1 26
$9.6B
Q4 25
$10.2B
Q3 25
$15.7B
Q2 25
$12.6B
Q1 25
$10.9B
Q4 24
$10.3B
Q3 24
$7.9B
Q2 24
$6.3B
Total Debt
BMY
BMY
CB
CB
Q1 26
$-42.2B
Q4 25
$44.8B
$15.7B
Q3 25
$48.7B
$15.7B
Q2 25
$48.9B
$13.5B
Q1 25
$49.5B
$14.5B
Q4 24
$49.4B
$14.4B
Q3 24
$49.5B
$14.6B
Q2 24
$52.0B
$13.2B
Stockholders' Equity
BMY
BMY
CB
CB
Q1 26
Q4 25
$18.5B
$73.8B
Q3 25
$18.6B
$71.9B
Q2 25
$17.4B
$69.4B
Q1 25
$17.4B
$65.7B
Q4 24
$16.3B
$64.0B
Q3 24
$17.1B
$65.8B
Q2 24
$17.0B
$61.0B
Total Assets
BMY
BMY
CB
CB
Q1 26
Q4 25
$90.0B
$272.3B
Q3 25
$96.9B
$270.2B
Q2 25
$94.7B
$261.6B
Q1 25
$92.4B
$251.8B
Q4 24
$92.6B
$246.5B
Q3 24
$93.7B
$250.6B
Q2 24
$94.6B
$238.6B
Debt / Equity
BMY
BMY
CB
CB
Q1 26
Q4 25
2.43×
0.21×
Q3 25
2.63×
0.22×
Q2 25
2.81×
0.19×
Q1 25
2.85×
0.22×
Q4 24
3.03×
0.22×
Q3 24
2.89×
0.22×
Q2 24
3.05×
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BMY
BMY
CB
CB
Operating Cash FlowLast quarter
$4.1B
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.26×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BMY
BMY
CB
CB
Q1 26
Q4 25
$2.0B
$4.1B
Q3 25
$6.3B
$3.6B
Q2 25
$3.9B
$3.6B
Q1 25
$2.0B
$1.6B
Q4 24
$4.4B
$4.6B
Q3 24
$5.6B
$4.3B
Q2 24
$2.3B
$4.1B
Free Cash Flow
BMY
BMY
CB
CB
Q1 26
Q4 25
$1.6B
Q3 25
$6.0B
Q2 25
$3.6B
Q1 25
$1.7B
Q4 24
$4.1B
Q3 24
$5.3B
Q2 24
$2.1B
FCF Margin
BMY
BMY
CB
CB
Q1 26
Q4 25
12.8%
Q3 25
49.0%
Q2 25
29.0%
Q1 25
15.1%
Q4 24
32.9%
Q3 24
44.3%
Q2 24
16.9%
Capex Intensity
BMY
BMY
CB
CB
Q1 26
Q4 25
3.0%
Q3 25
2.6%
Q2 25
2.9%
Q1 25
2.3%
Q4 24
3.1%
Q3 24
2.7%
Q2 24
2.1%
Cash Conversion
BMY
BMY
CB
CB
Q1 26
Q4 25
1.82×
1.26×
Q3 25
2.87×
1.30×
Q2 25
2.99×
1.20×
Q1 25
0.80×
1.18×
Q4 24
61.65×
1.77×
Q3 24
4.62×
1.86×
Q2 24
1.38×
1.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons